Albiglutide

Most common in the first 2-4 weeks of treatment or after dose escalation. Usually resolves within 1-2 weeks. Manage by taking small, frequent meals; avoiding fatty or spicy foods; and staying hydrated. Antiemetics (e.g., ondansetron) may be considered if severe.

Occurs in approximately 5-10% of patients, typically early in treatment. If persistent or severe, contact a healthcare provider. Ensure adequate hydration to prevent dehydration.

Reported in 10-20% of patients. Usually mild and self-limiting within 1-2 weeks. Manage with adequate hydration and dietary adjustments (increase soluble fiber gradually). Antidiarrheal agents (e.g., loperamide) may provide temporary relief.

Less common than diarrhea but can occur. Manage with increased water intake, dietary fiber, and physical activity. Stool softeners may help if needed.

Mild to moderate abdominal pain or cramping may occur, particularly early in treatment. Usually resolves within 1-2 weeks. Severe or persistent abdominal pain warrants medical evaluation.

Reported in a small percentage of patients. Usually mild and self-resolving. Over-the-counter analgesics (e.g., acetaminophen) may provide relief.

Risk is low when used as monotherapy but increases when combined with insulin or sulfonylureas. Symptoms include tremor, sweating, palpitations, and confusion. Manage by consuming 15 g of fast-acting carbohydrates (e.g., glucose tablets, juice). Dose adjustment of concomitant medications may be necessary.

Mild erythema, swelling, or pruritus at the injection site may occur. Typically resolves within hours to days. Ensure proper site rotation to prevent lipodystrophy. Topical hydrocortisone cream may reduce inflammation if needed.

Occurs with repeated injections at the same site. Prevent by rotating injection sites systematically with each dose. If lipodystrophy develops, avoid injecting into affected areas until normal appearance returns (may take weeks to months).

Rare but serious adverse event. Symptoms include severe upper abdominal pain, back pain, nausea, and vomiting. Seek immediate medical attention if suspected. GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Rapid weight loss may increase risk of gallstone formation. Symptoms include right upper quadrant pain, nausea, and vomiting. Seek medical evaluation if symptoms develop. Risk may be reduced by gradual weight loss.

Mild increases in resting heart rate have been observed in some patients. Usually asymptomatic and resolves with continued use. Monitor heart rate; contact a healthcare provider if symptoms of palpitations or chest discomfort develop.

May occur due to nausea, vomiting, or diarrhea. Ensure adequate fluid intake (at least 2-3 liters of water daily). Symptoms include dry mouth, dizziness, and reduced urination. Seek medical attention if severe.

Rare but serious. Symptoms include rash, urticaria, angioedema, difficulty breathing, or anaphylaxis. Seek immediate medical attention if any signs of allergic reaction develop. Albiglutide is contraindicated in patients with known hypersensitivity to albiglutide or any component of the formulation.